DNLI earnings analysis
What we found in DNLI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Denali Therapeutics reported a net loss of $128.4 million in Q1 2026, an improvement from a loss of $133.0 million in Q1 2025. Despite entering the commercial phase with the FDA approval of AVLAYAH for Hunter syndrome in March 2026, the company continues to face significant operational losses and relies heavily on ongoing capital to sustain its strategies.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved Net Loss
- Net loss narrowed to $128.4M in Q1 2026 from $133.0M in Q1 2025.
- Successful Product Launch
- Launch of AVLAYAH, FDA approved for Hunter syndrome, officially commenced in April 2026.
- Cash Reserves
- Cash, cash equivalents and marketable securities totaled approximately $1.05 billion as of March 31, 2026.
- Reduced R&D Expenses
- R&D expenses declined to $103.8M in Q1 2026, down from $116.2M in Q1 2025.
- Increased G&A Expenses
- G&A expenses increased by 14% to $33.5M compared to $29.4M in Q1 2025.
- Funding Success
- Received $200.0 million gross proceeds under a synthetic royalty agreement with Royalty Pharma following AVLAYAH’s approval.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Operating Losses
- Continuing significant losses totaling $128.4M for Q1 2026 may impact sustainability.
- Dependency on Product Success
- Future revenue highly reliant on successful commercialization of AVLAYAH.
- Competition and Market Acceptance Risks
- AVLAYAH may struggle to establish adequate market acceptance due to competition and pricing pressures.
What they said about what is next.
No specific numeric guidance was provided for future quarters.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 26, 2026
- Denali Therapeutics reported substantial ongoing net losses totaling $512.5 million for the year ending December 31, 2025. Although the company continues to advance the development of its product pipeline, including…
- 10-Q · November 6, 2025
- Denali Therapeutics reported a challenging third quarter for 2025 with no reported revenue and net losses increasing to approximately $126.9 million, up from $107.2 million in Q3 2024. The company also faced significant…
- 10-Q · August 11, 2025
- Denali Therapeutics reported a continued lack of revenue for Q2 2025 but demonstrated a minor improvement in EPS, reported at -$0.72 against a consensus estimate of -$0.74. Operating expenses rose due to increased…
- 10-Q · May 6, 2025
- Denali Therapeutics reported no revenue for Q1 2025, continuing an ongoing trend of significant operating losses with an EPS of -0.78, underperforming compared to prior loss periods and expectations. Operating expenses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DNLI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever